Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: EW 4 – 2 PHG Matrix Metrics: EW 9 – 1 PHG

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin).

  • Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and PHG (28.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs PHG
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
PHG NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$30.21
-0.43% 1D
Market Cap $29.6B
TTM Revenue $8.71B
Forward P/E 14.9x
Beta / 30D Vol 0.73β · 38% Vol
Unified Composite Score
28.4 / 100 SELL
Tech 50.0 Fund 23.0 Flow 54.0 Mom 11.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.4% over 20 days), RSI 71
RSI-14: 71.0 · SMA20: $28.51 · SMA50: $26.23

6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 PHG)

Columns: Metric · EW · PHG
1. Valuation Multiples PHG
Forward P/E 31.6x 14.9x
Trailing P/E 61.5x 63.2x
PEG Ratio 2.33x 0.90x
EV / Revenue 8.8x 3.7x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +2.1%
Earnings Growth (YoY) +6.7% -85.4%
TTM Revenue (USD) $6.67B $8.71B
Market Cap $60.8B $29.6B
3. Profitability & Quality EW
Gross Margin 78.0% 46.4%
Operating Margin 28.8% 8.8%
Net Profit Margin 15.3% 5.4%
Return on Equity (ROE) 9.3% 8.6%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $1.42B $895M
Cash Flow Margin 21.3% 10.3%
Net Cash / Leverage $2.41B Net Cash $2.64B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHG
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 24.6% (34th %ile) 25.8% (2nd %ile)
Put/Call OI Skew N/A 0.30x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 37.6% of Rev ($3.27B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (9) vs PHG (1)
Institutional Metric EW PHG Criterion Row Edge
Market Capitalization
Scale
$60.8B $29.6B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 63.2x Lower Multiple EW
Forward P/E Ratio
Valuation
31.6x 14.9x Lower Multiple PHG
Revenue Growth (YoY)
Growth
+10.5% +2.1% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 8.8% Higher Margin EW
Net Profit Margin
Profitability
15.3% 5.4% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
9.3% 8.6% Higher ROE EW
52-Week Range Position
Momentum
96% ($75–$108) 67% ($24–$33) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.73β · 38% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 28.4 / 100 (SELL) Higher Composite EW
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $8.71B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 0.90x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $895M ($2.64B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +5.79 pp
EW: +23.16% · PHG: +17.37%
3M Horizon EW +5.75 pp
EW: +17.23% · PHG: +11.48%
6M Horizon EW +13.48 pp
EW: +29.45% · PHG: +15.97%
1Y Horizon EW +19.4 pp
EW: +23.86% · PHG: +4.46%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue PHG Revenue EW Op. Margin PHG Op. Margin Margin Leader
Q3 '25 $6.21B $8.44B 27.4% 7.7% EW
Q4 '25 $6.28B $10.0B 23.6% 11.1% EW
Q1 '26 $6.59B $7.66B 31.2% 6.2% EW
Q2 '26 $6.96B $8.55B 29.8% 14.0% EW
Q3 '26 $6.86B $8.62B 30.2% 3.8% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
8d in phase · OBV DISTRIBUTION
Current IV 25.8%
IV Percentile 2nd %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $29.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($3.27B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs PHG Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and PHG (28.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $8.71B TTM revenue (46.4% gross margin, 8.8% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), EW cumulative revenue shifted +10.5% while PHG shifted +2.1%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($3.27B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas PHG trades at 14.9x Forward P/E, 63.2x Trailing P/E, 0.90x PEG, and 3.7x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, PHG carries 25.8% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.73β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.